Abstract: A framework for an improved destruction of interrelated data objects is described herein. In one embodiment, destruction and/or archiving of data objects are decoupled from the destruction and/or archiving of a master data object by using a backup table. Before being destructed, attributes relevant to destruction of dependent data objects are copied from the master data object to the backup table. Subsequent destruction operations performed on data objects dependent on the master data object may attempt to retrieve the attributes relevant to destruction from the master data object itself, or from the backup table. In this way, data object destruction orderings are avoided, enabling dependent data objects to be destructed at any time.

Abstract: A framework for an improved destruction of interrelated data objects is described herein. In one embodiment, destruction and/or archiving of data objects are decoupled from the destruction and/or archiving of a master data object by using a backup table. Before being destructed, attributes relevant to destruction of dependent data objects are copied from the master data object to the backup table. Subsequent destruction operations performed on data objects dependent on the master data object may attempt to retrieve the attributes relevant to destruction from the master data object itself, or from the backup table. In this way, data object destruction orderings are avoided, enabling dependent data objects to be destructed at any time.

Abstract: The treatment and/or prevention of depression by the co-administration of an estrogen with the progestin dienogest for HRT and/or contraception.

Abstract: The invention relates to application systems for buccal application, comprising 17?-estradiol in a dosage of 50 to 400 ?g, preferably 200 to 400 ?g, particularly preferably 300 ?g, together with one or more pharmaceutically acceptable additives or media for implementing the treatment or minimization of hot flashes in women having estrogen deficiencies.

Abstract: The pharmaceutical preparation for oral contraception has 28 daily dosage units, of which at least 21 daily dosage units each contain from 1.5 mg to 2 mg of dienogest and from 0.015 mg to 0.02 mg of ethinyl estradiol together in a pharmaceutically acceptable carrier. Seven or fewer daily dosage units contain no effective ingredient. Each daily dosage unit can be a film tablet for oral administration, which has a tablet core and film coating on the tablet core. At least 30% of the dienogest is released from the tablet core preferably in a delayed manner after more than 30 minutes, while at least 70% of the dienogest and ethinyl estradiol are released from the film coating preferably in 30 minutes, as determined by a standard dissolution test.

Abstract: The use of melatonin for the production of peroral pulsatile forms of medications assures the safeguard of an effective level of the medical substance of melatonin in the blood, and which realize a relatively short invasion phase with a controlled delivery in comparison to conventional forms of medication containing melatonin, and which simultaneously exclude the known side effects. A control of the delivery of the melatonin is effected which is associated with the precise adaptation to the illness episodes or the pain attacks of certain illnesses, which can be treated prophylactically and therapeutically with the active agent melatonin.